secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0000950170-24-020125
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reports Q4 net loss $161.5M; cash $1.85B; pipeline on track for pivotal trials
--------------------------------------------------------------------------------

- Q4 2023 net loss $161.5M vs $56.5M YoY; full year net loss $436.4M vs $248.7M YoY.
- Revenue fell to $0.7M (Q4) and $11.6M (FY) due to Sanofi collaboration termination in 2023.
- Cash, equivalents and securities $1.85B as of Dec 31, 2023, up from $644.9M a year ago (EQRx acquisition and equity offering).
- Plans to start pivotal Phase 3 trials for RMC-6236 in 2L NSCLC and 2L PDAC in H2 2024.
- 2024 GAAP net loss guidance $480M-$520M; cash runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/0000950170-24-020125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024020125/rvmd-20240226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-020125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer